

# Global Evaluation of the Interstitial Lung Disease (ILD) Diagnostic Pathway in the Post-COVID Era (ILD vMDT)

**First published:** 01/06/2022

**Last updated:** 08/08/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS47537

---

### Study ID

47538

---

### DARWIN EU® study

No

---

### Study countries


 Argentina


 Australia


 Austria

 Belgium

-  Brazil
-  Canada
-  Chile
-  Croatia
-  Denmark
-  Ecuador
-  Egypt
-  Finland
-  France
-  Germany
-  Greece
-  India
-  Indonesia
-  Ireland
-  Italy
-  Japan
-  Luxembourg
-  Malaysia
-  Mexico
-  New Zealand
-  Norway
-  Peru
-  Poland
-  Portugal
-  Romania
-  Singapore
-  South Africa
-  Spain
-  Sweden
-  Switzerland

 Türkiye

 United Kingdom

 United Kingdom (Northern Ireland)

 United States

---

## Study description

This study aims to identify characteristics of fibrotic interstitial lung disease (ILD) diagnostic practice and the features, strengths and limitations of distanced virtual multi-disciplinary team (vMDT) meetings, and open discussion on the prevalence of post-COVID fibrosis. An on-line survey will be sent via email to dedicated and non-dedicated ILD centres and countries within both mature and expanding economies (featuring a wide range of health systems and health infrastructures) across key global regions. The study will take an inclusive approach, welcoming responses from all countries and participants involved in the diagnosis of ILD.

---


## Study status


Finalised

## Research institutions and networks

### Networks






#### Respiratory Effectiveness Group (REG)

 Belgium

 Denmark

 France

 Germany

-  Greece
-  Hungary
-  Italy
-  Netherlands
-  Spain
-  Sweden
-  United Kingdom

**First published:** 07/07/2021

**Last updated:** 04/06/2024

**Network**

**ENCePP partner**

## Contact details

### Study institution contact

Lough Graham [enquiries@regresearchnetwork.org](mailto:enquiries@regresearchnetwork.org)

**Study contact**

[enquiries@regresearchnetwork.org](mailto:enquiries@regresearchnetwork.org)

### Primary lead investigator

Lough Graham

**Primary lead investigator**

## Study timelines

**Date when funding contract was signed**

Planned: 19/05/2022

Actual: 19/05/2022

---

### **Study start date**

Planned: 20/05/2022

Actual: 20/05/2022

---

### **Data analysis start date**

Planned: 23/05/2022

Actual: 24/05/2022

---

### **Date of interim report, if expected**

Planned: 23/05/2022

Actual: 25/05/2022

---

### **Date of final study report**

Planned: 31/05/2022

Actual: 31/05/2022

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Boehringer Ingelheim

## Study protocol

[REG ILD eMDT protocol REG-RES2021 v1.pdf](#) (2.06 MB)

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

Study type

Study type list

**Study topic:**

Other

---

**Study topic, other:**

Disease/Epidemiology study

**Study type:**

Non-interventional study

---

**Scope of the study:**

Other

**If 'other', further details on the scope of the study**

Descriptive analysis of ILD diagnostic pathway

**Data collection methods:**

**Main study objective:**

This study aims to identify characteristics of fibrotic interstitial lung disease (ILD) diagnostic practice and the features, strengths and limitations of distanced virtual multi-disciplinary team (vMDT) meetings, and open discussion on the prevalence of post-COVID fibrosis.

## Study Design

**Non-interventional study design**

Other

---

**Non-interventional study design, other**

Electronic systematic survey

## Population studied

**Short description of the study population**

The study focused on interstitial lung disease (ILD) MDTs or eMDTs diagnoses center.

---

**Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
-

## Estimated number of subjects

400

## Study design details

### Data analysis plan

Descriptive statistics, Mann-Whitney U tests, Kruskal-Wallis tests, Chi2 or Fischer's exact tests (as appropriate).

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

[Other](#)

---

### Data sources (types), other

An online survey will be sent to ILD centres for a representative to complete. There is no data on patients collected.

## Use of a Common Data Model (CDM)

## **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No